Postponement and Re-scheduling of Annual General Meeting
Rhea-AI Summary
Biodexa Pharmaceuticals (Nasdaq: BDRX), a clinical-stage biopharmaceutical company focused on gastrointestinal cancers, adjourned its Annual General Meeting on June 17, 2026 due to lack of quorum.
The AGM is re-scheduled for 11:00am BST on June 30, 2026 at the company’s Cardiff offices, and previously submitted proxies remain valid.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – BDRX
On the day this news was published, BDRX gained 1.66%, reflecting a mild positive market reaction. This price movement added approximately $38K to the company's valuation, bringing the market cap to $2.35M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
BDRX is down 2.93% while momentum peers DRMA and SLXN show declines of about 3.0% and 2.8%, alongside mixed action in TOVX, consistent with broader Healthcare/Biotech pressure.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 14 | Shareholder letter | Negative | -8.5% | Letter outlining major share capital reorganisation ahead of June 17, 2026 AGM. |
| Apr 02 | Partnership announcement | Positive | +42.2% | Partnership with Syngene to manufacture MTX240 GMP clinical trial supplies. |
| Mar 31 | Access program launch | Positive | +1.0% | Global Early Access / Named Patient Program for eRapa in FAP patients. |
| Mar 27 | Preliminary results | Neutral | -6.5% | Audited preliminary results released for year ended 31 December 2025. |
| Mar 23 | Access program launch | Positive | -2.4% | Global Early Access Program for eRapa via strategic partnership with Tanner Pharma. |
Recent news shows large positive reactions to partnership/clinical supply updates, while capital structure and results announcements have often coincided with share price weakness.
Regulatory & Risk Context
Market Pulse Summary
This announcement highlights an AGM adjournment for lack of quorum, with the meeting reset to June 30, 2026 at 11.00am BST. Investors may watch how shareholders respond to previously flagged capital reorganisation proposals and any governance follow-ups.
AI-generated analysis. Not financial advice.
June 17, 2026
Biodexa Pharmaceuticals PLC
Postponement and Re-scheduling of Annual General Meeting
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces that its Annual General Meeting (“AGM”) scheduled for 11.00am BST today was adjourned due to lack of a quorum.
In accordance with the Company’s articles of association, the AGM cannot be reconvened for 10 clear days. Accordingly, the AGM has been re-scheduled for 11.00am BST on June 30, 2026 at the Company’s offices at 1 Caspian Point, Caspian Way, Cardiff CF10 4DQ.
Proxies submitted in time for the original AGM will remain valid for the re-scheduled AGM.
ENDS
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, MTX240 under development for Gastrointestinal Stromal Tumors (GIST) and tolimidone, under development for the treatment of type 1 diabetes.
eRapa is a proprietary oral capsule formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.
MTX240 is a molecular glue, bringing two intracellular proteins, PDE3a and SLFN12, specifically co-expressed by GIST cancer cells, into close proximity to form a stable complex. This interaction stabilizes SLFN12, enabling it to drive RNase-mediated apoptosis in GIST cells through a mechanism independent of KIT signalling.
Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.
Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
